The finding is especially exciting because E64d has previously been shown safe for use in humans, so we believe the compound has strong potential as a new therapy for Alzheimer's disease...Alzheimer's Reading Room
Researchers at the University of California, San Diego, the Medical University of South Carolina and American Life Science Pharmaceuticals of San Diego have demonstrated that oral administration of a cysteine protease inhibitor, E64d, not only reduces the build-up of β-amyloid (Aβ) in the brains of animal models for Alzheimer's disease, but also results in a substantial improvement in memory deficit.







































